Ebola vaccines

Description

Two types of Ebola vaccines have been licensed and prequalified by WHO – the live, attenuated, single-dose rVSV∆G-ZEBOV-GP vaccine (Ervebo, Merck & Co.) and the heterologous, two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen (Zabdeno and Mvabea, Janssen Pharmaceutical). Both are recommended against Ebola virus disease. They are not recommended against disease cause by other virus of the Orthoebolavirus genus. The single-dose single-dose rVSV∆G-ZEBOV-GP vaccine (Ervebo, Merck & Co.) is recommended for both outbreak response and preventive vaccination of health care and frontline workers in at-risk countries. A stockpile of vaccine doses has been established for reactive use and is management by the International Coordinating Group for vaccine provision. The two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen (Zabdeno and Mvabea, Janssen Pharmaceutica) is recommended for preventive use, outside of an outbreak response, in health care and frontline workers in at-risk countries. For more recommendation, see SAGE recommendations https://iris.who.int/bitstream/handle/10665/378109/WER9927-355-362.pdf?sequence=1&isAllowed=y